President Joe Biden and Senator Bernie Sanders have urged Novo Nordisk and Eli Lilly to lower the prices of their popular weight loss drugs.
Tags: Novo Nordisk
Novo Nordisk, Septerna Launch $2.2 Billion Collaboration on Obesity Treatments
Novo Nordisk partners with Septerna in a $2.2 billion deal to develop oral treatments for obesity, type 2 diabetes, and other metabolic diseases.
Wegovy Maker Novo Nordisk Dismisses Fears of Falling Behind Eli Lilly, Sees Strong Growth Ahead
Novo Nordisk reassures investors with strong growth forecasts, rising GLP-1 drug demand, and promising new treatments despite market challenges.
Wegovy Now Available to 180 Million Obese in China at $194, Also Not Covered by Insurance
Novo Nordisk launches Wegovy in China, offering an effective weight-loss solution for about 180 million obese Chinese population, though not covered by insurance.
Weight Loss Drugs Users 33% Less Likely to Die From Covid-19, Study Reveals
A new study reveals that semaglutide, a key ingredient in Ozempic and Wegovy, reduces the risk of dying from Covid-19 by 33%, [otentially boosting its market value.
Latest News
Novo Nordisk announced a $4.1 billion investment to build a new manufacturing plant in Clayton, North Carolina, to increase production capacity for its popular drugs Wegovy, Ozempic, and other injectable therapies.
Novo Nordisk CEO Lars Fruergaard Jørgensen will testify before the Senate following Sen. Bernie Sanders' threat to subpoena the company over the pricing of diabetes drug Ozempic and obesity drug Wegovy.
Telehealth startup Ro has launched a free online tracker to help patients and doctors locate in-stock weight-loss drugs like Wegovy amid national shortages, providing real-time availability and the option to report outages to the FDA.
Amgen witnessed an impressive 12% surge in its shares on Friday, marking its most substantial single-day increase in nearly 15 years.
The Bill & Melinda Gates Foundation, Novo Nordisk Foundation, and Wellcome Trust collaborated to solve global health concerns using science and technology.
Novo Nordisk exceeded profit expectations in Q1 2024 with a 28% surge in net profit, driven by Wegovy's success.
A recent study suggests that Novo Nordisk's diabetes drug, Ozempic, priced at nearly $1,000 in the US, could be produced for less than $5 a month.
The successful weight loss trial of the amycretin pill pushed Novo Nordisk past Tesla in market value to $604 billion, increasing investor interest in innovative solutions for major health issues like obesity.
Danish pharmaceutical group Novo Nordisk plans to use 500 of its 3,000-strong sales force in the United States to promote its new obesity drug, executive vice president Jakob Riis told Reuters on Monday.
